1298 related articles for article (PubMed ID: 21974995)
21. Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents.
Machado AA; Machado CM; Boas LS; Lopes MC; Gouvêa Ade F; Succi RC; Mendoza TR; Kanashiro TM; Machado DM
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):999-1003. PubMed ID: 21284525
[TBL] [Abstract][Full Text] [Related]
22. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
[TBL] [Abstract][Full Text] [Related]
26. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
27. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
28. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
29. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
Phongsamart W; Sirisanthana V; Wittawatmongkol O; Maleesatharn A; Sudjaritruk T; Chearskul P; Aurpibul L; Sirisanthana T; Chokephaibulkit K
Vaccine; 2011 Nov; 29(47):8705-11. PubMed ID: 21893147
[TBL] [Abstract][Full Text] [Related]
31. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
32. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
33. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
34. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.
Fabbiani M; Di Giambenedetto S; Sali M; Farina S; Sansonetti P; Tamburrini E; Dal Verme LZ; Delogu G; De Luca A; Kelvin D; Cauda R; Fadda G
Vaccine; 2011 Apr; 29(16):2836-9. PubMed ID: 21349364
[TBL] [Abstract][Full Text] [Related]
35. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
36. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
[TBL] [Abstract][Full Text] [Related]
37. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
[TBL] [Abstract][Full Text] [Related]
38. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
39. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
40. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial.
Uno S; Kimachi K; Kei J; Miyazaki K; Oohama A; Nishimura T; Ibaragi K; Odoh K; Kudo Y; Kino Y
Microbiol Immunol; 2011 Nov; 55(11):783-9. PubMed ID: 21895745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]